Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TGF-β controls epigenetic re-programing of IFN-antiviral trained immunity and impairs virologic control in SIV-infected rhesus macaques [scMultiome]

ABSTRACT: Current immunotherapeutic approaches to eliminate latently HIV-infected cells have focused on targeting the adaptive arm of the immune system using vaccines and passive transfer of broadly neutralizing antibodies (bNAbs). Epigenetic reprogramming of innate myeloid cells triggered by adjuvants was recently shown to promote a state of interferon (IFN)-induced antiviral immunity and resistance to heterologous viral infections. Herein, flow cytometry, bulk and single-cell RNA-Seq/ATAC-Seq were performed on samples from a cohort of SIV-infected, virologically suppressed rhesus macaques (RMs) treated with anti-IL-10 and anti-PD-1 monoclonal antibodies (combo treatment) prior to analytical treatment interruption (ATI). These experiments revealed that combo treatment led to selective changes in chromatin accessibility, expression of IRF7/3 and STAT1, and expression of IFN-stimulated antiviral genes in myeloid cells and CD4+ T cells. These RMs showed a stringent and prolonged control of SIV viral rebound following ATI and a decay in levels of cell-associated viral DNA (CA-vDNA) in lymph nodes. These RMs showed reduced chromatin accessibility for the SMAD2/SMAD3, AP-1, and NFKB1 loci and lower expression of TGF-b and SMADs target genes. This signature is consistent with that observed in HIV elite controllers, who maintain undetectable levels of virus in the absence of ART and whose HIV reservoir size is small. These results highlight the critical role of the interplay between TGF-b and IFN in epigenetically regulated innate antiviral immune responses that can impact the viral reservoir.

ORGANISM(S): Macaca mulatta

PROVIDER: GSE279314 | GEO | 2026/02/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

TGF-β controls epigenetic re-programing of IFN-antiviral trained immunity and impairs virologic control in SIV-infected rhesus macaques [bulk RNA-seq]

Project description:Current immunotherapeutic approaches to eliminate latently HIV-infected cells have focused on targeting the adaptive arm of the immune system using vaccines and passive transfer of broadly neutralizing antibodies (bNAbs). Epigenetic reprogramming of innate myeloid cells triggered by adjuvants was recently shown to promote a state of interferon (IFN)-induced antiviral immunity and resistance to heterologous viral infections. Herein, flow cytometry, bulk and single-cell RNA-Seq/ATAC-Seq were performed on samples from a cohort of SIV-infected, virologically suppressed rhesus macaques (RMs) treated with anti-IL-10 and anti-PD-1 monoclonal antibodies (combo treatment) prior to analytical treatment interruption (ATI). These experiments revealed that combo treatment led to selective changes in chromatin accessibility, expression of IRF7/3 and STAT1, and expression of IFN-stimulated antiviral genes in myeloid cells and CD4+ T cells. These RMs showed a stringent and prolonged control of SIV viral rebound following ATI and a decay in levels of cell-associated viral DNA (CA-vDNA) in lymph nodes. These RMs showed reduced chromatin accessibility for the SMAD2/SMAD3, AP-1, and NFKB1 loci and lower expression of TGF-b and SMADs target genes. This signature is consistent with that observed in HIV elite controllers, who maintain undetectable levels of virus in the absence of ART and whose HIV reservoir size is small. These results highlight the critical role of the interplay between TGF-b and IFN in epigenetically regulated innate antiviral immune responses that can impact the viral reservoir.

2026-02-06 | GSE279313 | GEO

Type I IFN responses in rhesus macaques prevent SIV transmission and slow disease progression

Project description:In acute HIV infection immune activation may provide target cells and drive virus replication, which innate immunity may limit. Thus, the net effects of inflammatory mediators, including type I interferon (IFN-I), are unclear. Here, we block IFN-I signaling during pathogenic acute SIV infection with an IFN-I receptor antagonist. Delayed antiviral gene expression, increased SIV reservoir, increased CD4 T cell depletion and accelerated progression to AIDS and death ensue despite decreased T cell activation. In contrast, IFNα2a treatment initially upregulates antiviral genes and prevents systemic SIV infection after rectal challenge. Antiviral gene expression normalizes, and infection ensues with fewer transmitted/founder variants. Continued IFNα2a treatment causes delayed antiviral gene expression, increased SIV reservoir and increased CCR5+ CD4 T cell loss. Thus, the precise timing of antiviral gene expression has a profound impact on disease course. The benefits of early antiviral activity outweigh the harms of increased immune activation in acute SIV infection. SRA Study accession: SRP034563, BioProject ID:PRJNA231884

2014-07-23 | E-GEOD-53690 | biostudies-arrayexpress

Type I IFN responses in rhesus macaques prevent SIV transmission and slow disease progression

2014-07-23 | GSE53690 | GEO

Short-term pIFN-α2a treatment does not significantly reduce the viral reservoir of SIV-infected, ART-treated rhesus macaques

Project description:Objective: To evaluate the effect of short-term type I IFN treatment on the latent viral reservoir in SIV-infected rhesus macaques on ART; Methods: We infected twelve RMs intrarectally with 10,000 TCID of SIVmac239. After 6 weeks of infection, all RMs started a three-class, four-drug ART regimen. Once viral loads were consistently undetectable, six animals were administered 1 dose of pegylated IFN-α2a per week for 4 weeks with each weekly intramuscular application being 6 µg/kg.

2018-05-17 | GSE114561 | GEO

Reduced chronic lymphocyte activation following Interferon-α blockade in the acute phase of SIV infection in rhesus macaques

Project description:Pathogenic HIV/SIV infection of humans and rhesus macaques (RMs) induces persistently high production of type-I interferon (IFN-I) which is thought to contribute to disease progression. To elucidate the specific role of IFN in SIV pathogenesis, 12 RMs were treated prior to i.v. SIVmac239 infection with a high or a low dose of an antibody (AGS-009) that neutralizes most IFN subtypes, and compared with six mock-infused, SIV-infected controls. Plasma viremia was measured post infection to assess the effect of IFNα blockade on virus replication, and peripheral blood and lymphoid tissue samples were analyzed by immunophenotypical staining. Consistent with the known antiviral effect of IFN-I, high-dose AGS-009 treatment induced a modest increase in acute phase viral loads vs. controls. 4 out of 6 RMs receiving a high dose of AGS-009 also experienced an early decline in CD4+ T cell counts which was associated with progression to AIDS. Interestingly, 50% of animals treated with AGS-009 (6/12) developed AIDS within one year of infection, compared with 17% (1/6) of untreated controls. Finally, blockade of IFN decreased the levels of activated CD4+ and CD8+ T cells, as well as B-cells, as measured by PD-1 and/or Ki67 expression. The lower levels of activated lymphocytes in IFN-blockade animals supports the hypothesis that IFN signaling contributes to lymphocyte activation during SIV infection, and suggests that this signaling pathway is involved in controlling virus replication during acute infection. The potential anti-inflammatory effect of IFN blockade should be explored as a strategy to reduce immune activation in HIV-infected individuals.

2018-02-19 | GSE110617 | GEO

Deep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activation

Project description:Recent studies of nonhuman primates (NHPs) have suggested that during the acute phase of infection, antiviral mucosal immunity is restricting viral replication in the primary infection compartment. These studies imply that HIV achieves systemic infection as a consequence of a failure in host antiviral immunity. Here, we used high-dose intrarectal inoculation of rhesus macaques with SIVmac251 to examine how the mucosal immune system is overcome by SIV during acute infection. The host response in rectal mucosa was characterized by mRNA deep sequencing (mRNA-seq) at 3 and 12 days post inoculation (DPI) in 4 animals for each time point. The eight RMs were intrarectally challenged with SIVmac251 using 1 mL of a high-dose inoculum (6000 TCID50/mL). SIV inoculates were deposited at a rectal depth of 25 mm from the anus. Baseline rectal samples were obtained 14 days prior to viral challenge by pinch biopsy.

2014-04-17 | E-GEOD-56845 | biostudies-arrayexpress

IL-21 and IFNalpha therapy rescues terminally-differentiated NK cells and limit SIV reservoir in ART-treated macaques [cohort3]

Project description:Unlike HIV infection, which progresses to AIDS absent suppressive anti-retroviral therapy (ART), nonpathogenic infections in natural hosts, such African green monkeys (AGMs), are characterized by a lack of gut microbial translocation and robust secondary lymphoid Natural Killer (NK) cell responses resulting in absence of chronic inflammation and limited SIV dissemination in lymph nodes (LN) B-cell-follicles, respectively. In a pathogenic infection model (i.e. ART-treated, SIVmac239-infected rhesus macaques; RMs), sequential Interleukin (IL)-21 and interferon (IFN)-alpha therapy generated terminally-differentiated blood NK cells (NKG2a/clowCD16+) with potent HLA-E-restricted activity in response to SIV-ENV peptides in contrast to control RMs, where less differentiated, IFN-gamma+ NK cells predominated. The frequency and cytolytic activity of NKG2a/clowCD16+ NK cells correlated with a reduction of replication-competent SIV in LN during ART and viral rebound delay following analytical treatment interruption. These data demonstrate that AGM-like NK cell differentiation profiles can be rescued in RMs to promote viral clearance in tissues.

2021-02-22 | GSE163442 | GEO

IL-21 and IFNalpha therapy rescues terminally-differentiated NK cells and limit SIV reservoir in ART-treated macaques [cohort2]

2021-02-22 | GSE163441 | GEO

IL-21 and IFNalpha therapy rescues terminally-differentiated NK cells and limit SIV reservoir in ART-treated macaques [cohort1]

2021-02-22 | GSE163440 | GEO

Viral rebound in SHIV-infected infant macaques is predicted by immunovirologic features measured before and after antiretroviral therapy

Project description:Evaluation of HIV cure strategies requires antiretroviral therapy (ART) interruption, but ethical and clinical considerations make this difficult in children. Uncovering predictors of time to viral rebound (TTR) and post-treatment control (PTC) of rebound viremia in a pediatric preclinical model may inform the design of studies testing novel cure interventions in these populations. We thus assessed 141 variables in SHIV-infected infant rhesus macaques (RMs) where ART initiation was staggered then followed by analytical treatment interruption (ATI). Viral rebound occurred in 25/30 RMs within 7-98 d of ATI, with TTR significantly delayed in the Early ART group compared to the Intermediate and Late ART groups (median TTR 84, 18, and 17 d, respectively; p<0.001). Peak plasma viral load pre-ART best described TTR, with increased predictive strength through the successive inclusion of six additional variables. Increased peak viral load pre-ART decreased the odds of no rebound and elevated Ki67+ effector memory CD8+ T cells in lymph nodes pre-ATI increased the odds of PTC. RNA sequencing of CD4+ T cells pre-ATI showed heme metabolism and IFNg response pathways were most upregulated in RMs with sustained suppression of viremia during ATI. Analysis of only the Early ART group also implicated TGFb pathway genes in lack of viral rebound off ART. This comprehensive investigation reveals major determinants of viral rebound dynamics following ART interruption that should be validated and explored as biomarkers to screen children with HIV being considered for ATI.

2025-09-11 | GSE261049 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data